The Best and Worst Dow Stocks

Page 2 of 29

28. Amgen Inc. (NASDAQ:AMGN)

Number of Hedge Fund Holders: 72

Short Interest as of Apr 30, 2025: 2.71%

Amgen Inc. operates as a manufacturer, developer, discoverer, and deliverer of human therapeutics. Its key product candidates are Enbrel, XGEVA, Otezla, KYPROLIS, Prolia, Repatha, Nplate, Aranesp, EVENITY, Vectibix, BLINCYTO, and others. It serves dialysis centers, pharmacies, hospitals, and physicians.

The firm recently announced plans to invest an additional $900 million to expand its Ohio biotech manufacturing facility. According to Bloomberg’s report, this expansion will create hundreds of new jobs. This move will help the company to improve its global biomanufacturing network.

Chairman and CEO at Amgen, Robert A. Bradway commented:

“Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988. Today’s investment reinforces our ongoing commitment to expanding U.S. manufacturing and ensuring patients around the world have access to our innovative medicines. Ohio offers a supportive business climate, skilled workforce, and strategic location, making it an ideal choice for this next phase of our investment.”

At the start of this month, the firm received an expanded FDA label approval for Uplizna. The FDA has approved it as the first treatment for Immunoglobulin G4-related disease (IgG4-RD) for adults. This approval is based on the late-stage clinical trial results indicating that Uplizna reduced the risk of disease reactivation by 87%.

Page 2 of 29